C12Y 117/04001
Ribonucleoside-diphosphate reductase
Official title: Ribonucleoside-diphosphate reductase (1.17.4.1)
C12Y117/04001 (Ribonucleoside-diphosphate reductase) appears on 13 US grants and 17 published applications in this corpus.
Search patents in C12Y- Granted patents
- 13
- Published applications
- 17
- Assignees
- 11
- Inventors
- 43
- Latest grant
- 23 Sep 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 1 |
| 2002 | 1 | 1 |
| 2003 | 1 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 1 | 1 |
| 2016 | 0 | 1 |
| 2017 | 0 | 1 |
| 2018 | 2 | 2 |
| 2019 | 0 | 0 |
| 2020 | 1 | 5 |
| 2021 | 1 | 1 |
| 2022 | 1 | 0 |
| 2023 | 0 | 0 |
| 2024 | 1 | 0 |
| 2025 | 2 | 2 |
By publication year. Applications have been published since 2001.
Recent patents
- Gene therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes23 Sep 2025US 12,419,970 B2The Trustees of Columbia University in the City of New York
- Engineering the RRM2 subunit of ribonucleotide reductase to resist degradation28 Jan 2025US 12,208,133 B2University of Washington
- Compositions and methods for inhibiting expression of RRM2 genes5 Mar 2024US 11,920,134 B2Arrowhead Pharmaceuticals, Inc.
- Enzyme products29 Mar 2022US 11,286,474 B2C-LEcta GmbH
- Methods and compositions useful in generating non canonical CD8+ T cell responses17 Aug 2021US 11,091,779 B2Oregon Health & Science University
- Generation of deoxyadenosine triphosphate donor cells and uses thereof8 May 2025US 2025/0145957 A1University of Washington
- Nucleic acid encoding rrm2 subunit of ribonucleotide reductase to resist degradation17 Apr 2025US 2025/0121038 A1University of Washington
- Gene therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes8 Apr 2021US 2021/0100917 A1The Trustees of Columbia University in the City of New York
- Use of ribonucleotide reductase alone or in combination with micro-dystrophin to treat duchenne muscular dystrophy striated muscle disease31 Dec 2020US 2020/0405824 A1University of Washington
- Methods and Compositions Useful In Generating Non Canonical CD8+ T Cell Responses17 Dec 2020US 2020/0392534 A1Oregon Health & Science University
Most cited
By later US patents
- Cell and gene based methods to improve cardiac function5US 9,868,937 B2University of Washington · 2018
- Methods of identifying compounds that inhibit DNA synthesis in mycobacterium tuberculosis and compositions, reagents and kits for performing the same4US 5,834,279 AThe Trustees of the University of Pennsylvania · 1998
- Combination viral-based and gene-based therapy of tumors2US 6,602,499 B1The General Hospital Corporation · 2003
- Methods and compositions useful in generating non canonical CD8+ T cell responses1US 11,091,779 B2Oregon Health & Science University · 2021
- Ribonucleotide diphosphate reductase, nrdF, of streptococcus pneumoniae1US 6,190,881 B1SmithKline Beecham Corporation · 2001